Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
First-line ibrutinib has long-term survival benefit
Barr PM et al. Haematologica. 2018;103(9):1502-10.
Key clinical point: First-line ibrutinib resulted in a long-term progression-free survival versus chemotherapy in older CLL patients.
Major finding: There was an 88% reduction in risk of progression-free survival events for those patients randomized to ibrutinib (P less than .0001).
Study details: Extended phase 3 results from the RESONATE-2 trial, including 269 older patients with untreated CLL or small lymphocytic lymphoma.
Disclosures: This study was supported by Pharmacyclics, an AbbVie company, and by grants from the National Institutes of Health and the MD Anderson Moon Shot Program in CLL. Pharmacyclics designed the study and performed analysis of the data.
Barr PM et al. Haematologica. 2018;103(9):1502-10.